| By Business Wire | Article Rating: |
|
| June 2, 2009 11:49 AM EDT | Reads: |
320 |
Technitrol, Inc. (NYSE:TNL) announced today that the company has entered into a definitive agreement with Altor Fund III (“Altor”) to sell its Medtech components business (“Medtech”) for $200 million in cash, subject to final working capital adjustments. Medtech includes the former Sonion A/S's balanced armature receivers, high-end microphones, and electromechanical devices for the hearing aid, high-end audio headset, and medical device markets. The business generated revenues of $110 million for the trailing twelve months ended March 31, 2009. Technitrol will retain the former Sonion business selling high-volume transducers mainly for speakers used in cell phones and similar communication devices. Medtech is headquartered in Denmark with manufacturing facilities in Vietnam and Poland.
Technitrol will apply the net sale proceeds to reduce its outstanding debt which will result in an immediate reduction in its debt-to-EBITDA leverage ratio. Additionally, the debt repayment will increase operating flexibility by reducing quarterly interest expense by approximately $2.0 million. The transaction is expected to close in late June or early July 2009.
Excluding Medtech for the entire year, revenues in Technitrol's remaining Electronic Components Group (“Electronics”) are expected to exceed $450 million in 2009 and to generate EBITDA in excess of $35 million.
The sale of Medtech will allow the remaining Electronics business of Technitrol to increase its focus on expanding its presence and penetration in its core markets, which are expected to benefit from technology transformation and infrastructure build-outs in the years ahead. Core markets for Electronics' components include:
- wireline communications (37% estimated pro forma Electronics revenue share), for use in switches, hubs, routers, and cable and telephony devices enabling voice, video and data (“triple-play”) services;
- wireless communications (38% estimated revenue share), for use in handsets, handheld devices, and machine-to-machine and wireless infrastructure devices used in voice and data networking, automotive and energy monitoring systems; and
- power electronics (25% estimated revenue share), for use in applications such as automotive electronic systems, power converters, voltage regulators, power-sensing equipment used in the “smart grid” and military/aerospace navigation and communication systems.
Technitrol also announced that it and its lender banks have agreed to modify the terms of its senior credit agreement to allow for this and subsequent business divestitures and for accelerated debt repayments.
Based in Philadelphia, Technitrol is a worldwide producer of electronic components, electrical contacts and assemblies and other precision-engineered parts and materials for manufacturers in the wireless and wireline communications, military/aerospace, automotive and electrical equipment industries. For more information, visit Technitrol's Web site at http://www.technitrol.com.
The Altor funds (Altor) are private equity funds comprising the “Altor 2003 Fund,” with committed capital of EUR 650 million, the “Altor Fund II,” with committed capital of EUR 1,150 million, and the “Altor Fund III,” with committed capital of EUR 2,000 million. Altor is advised by Altor Equity Partners. Altor invests in companies in the Nordic region with a focus on value creation through growth initiatives, strategic development and operational improvements. Among Altor’s investments are Lindorff, AGR Group (Listed on the Oslo Stock Exchange), Relacom, Ferrosan, Meyn, Aalborg Industries, PaloDEx, Navico, Byggmax, Nimbus Boats, SPT Group, PIAB, Dustin, Helly Hansen, Euro Cater, Vatus, Northstar, Wrist, Q-matic, Constructor, Papyrus, Carnegie and Max Matthiessen. Prior investments include ACO Hud AB (divested to Omega Pharma) and Dynapac (divested to Atlas Copco). For more information, please visit www.altor.com.
Cautionary Note: This message contains "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially. This release should be read in conjunction with the factors set forth in Technitrol's report on Form 10-Q for the quarter ended March 27, 2009 in Item 1a under the caption "Factors that May Affect Our Future Results (Cautionary Statements for Purposes of the 'Safe Harbor' Provisions of the Private Securities Litigation Reform Act of 1995)."
Copyright © 2009 Technitrol, Inc. All rights reserved. All brand names and trademarks are properties of their respective holders.
Published June 2, 2009 Reads 320
Copyright © 2009 Ulitzer, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
More Stories By Business Wire
Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
- Will Microsoft Buy Citrix?
- Virtualization Will Be the Highest-Impact IT Trend Through 2012
- Virtualization Conference & Expo 2009 West: Call for Papers Closing
- If VMware Is "Virtualization 1.0" Is Microsoft the Avatar Of "Virtualization 2.0"?
- Will VMware Still Exist in Five Years?
- Cisco Aims Higher Even Than Cloud Computing
- Scalable Pricing in a Scalable World
- Preparing Your Enterprise for Virtualization
- Trusting the Cloud: Timing and Adoption of Cloud Technologies
- Is Virtualization the Biggest Hype Ever?
- Cloud Storage: A Paradigm Shift in IT
- Elastic Computing vs. Cloud Computing


















Ulitzer content is offered under Creative Commons "Attribution Non-Commercial No Derivatives" License.
For any reuse or distribution, you must make clear to others the license terms of this work.
The best way to do this is with a link to this web page.
Any of the above conditions can be waived if you get written permission from Ulitzer, Inc., the copyright holder.
Nothing in this license impairs or restricts the author's moral rights.